383 related articles for article (PubMed ID: 26713296)
1. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.
Mirrakhimov AE
N Am J Med Sci; 2015 Nov; 7(11):483-93. PubMed ID: 26713296
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
[TBL] [Abstract][Full Text] [Related]
3. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy.
Sheehan MT; Wermers RA; Jatoi A; Loprinzi CL; Onitilo AA
Med Hypotheses; 2020 Oct; 143():110149. PubMed ID: 32763659
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature.
Asonitis N; Angelousi A; Zafeiris C; Lambrou GI; Dontas I; Kassi E
Horm Metab Res; 2019 Dec; 51(12):770-778. PubMed ID: 31826272
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia of malignancy and new treatment options.
Sternlicht H; Glezerman IG
Ther Clin Risk Manag; 2015; 11():1779-88. PubMed ID: 26675713
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review.
Sheehan M; Tanimu S; Tanimu Y; Engel J; Onitilo A
Case Rep Oncol; 2020; 13(1):321-329. PubMed ID: 32308599
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia of malignancy treated with cinacalcet.
Asonitis N; Kassi E; Kokkinos M; Giovanopoulos I; Petychaki F; Gogas H
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 29399364
[TBL] [Abstract][Full Text] [Related]
9. Cancer-related hypercalcemia and potential treatments.
Almuradova E; Cicin I
Front Endocrinol (Lausanne); 2023; 14():1039490. PubMed ID: 37033238
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia of Malignancy and Colorectal Cancer.
Galindo RJ; Romao I; Valsamis A; Weinerman S; Harris YT
World J Oncol; 2016 Feb; 7(1):5-12. PubMed ID: 26998187
[TBL] [Abstract][Full Text] [Related]
11. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Related Hypercalcemia.
Goldner W
J Oncol Pract; 2016 May; 12(5):426-32. PubMed ID: 27170690
[TBL] [Abstract][Full Text] [Related]
15. Role of Parathyroid Hormone Related Peptide (PTHrP) in Hypercalcemia of Malignancy and the Development of Osteolytic Metastases.
de Vernejoul MC
J Clin Rheumatol; 1997 Apr; 3(2 Suppl):109. PubMed ID: 19078166
[TBL] [Abstract][Full Text] [Related]
16. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
17. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy.
Jumpertz von Schwartzenberg R; Elbelt U; Ventz M; Mai K; Kienitz T; Maurer L; Rose T; Rückert JC; Strasburger CJ; Spranger J
Endocrinol Diabetes Metab Case Rep; 2015; 2015():150082. PubMed ID: 26605043
[TBL] [Abstract][Full Text] [Related]
18. [Refractory hypercalcemia in patient with lung cancer].
Grzywacz A; Dziuk M; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
[TBL] [Abstract][Full Text] [Related]
19. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
Rosner MH; Dalkin AC
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
[TBL] [Abstract][Full Text] [Related]
20. Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis.
Scheen M; Nowak G; Sanchez B; Teta D
Eur J Med Res; 2022 Jun; 27(1):89. PubMed ID: 35676731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
